Thinly traded Madrigal Pharmaceuticals (NASDAQ:MDGL) is up 13% premarket on light volume on the heels of its announcement of new data from a Phase 2 clinical trial evaluating resmetirom (MGL-3196) in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.
Once-daily oral treatment of 80 mg or 100 mg of
resmetirom (doses being tested in Phase 3) resulted in 50% and more than
60% reductions, respectively, in liver fat per new analyses of Phase 2
data. 60% of treated patients experienced reductions in fibrosis.
The company says its two Phase 3s, MAESTRO-NASH and MAESTRO-NAFLD-1,
are continuing without protocol changes. Guidance from regulators has
allowed for more flexible processes at trial sites amid COVID-19. New
screening has slowed down but disruptions have been minimal for trial
participants.
https://seekingalpha.com/news/3560466-madrigal-pharma-up-13-on-positive-data-on-nash-drug-resmetirom
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.